

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)
2. (Currently amended) ~~[[The]]~~ An isolated monocyte-derived multipotent cell ~~according to claim 1, further~~ expressing CD14, CD34, CD45 and type I collagen.
3. (Currently amended) The isolated monocyte-derived multipotent cell according to claim ~~[[1 or]]~~ 2, that ~~[[can]]~~ is able to differentiate into mesenchymal cells by a culture under a condition inducing differentiation into mesenchymal tissues.
4. (Currently amended) The isolated monocyte-derived multipotent cell according to claim 3, wherein the mesenchymal cells are osteoblasts, skeletal myoblasts, chondrocytes or adipocytes.
5. (Currently amended) The isolated monocyte-derived multipotent cell according to claim ~~[[1 or]]~~ 2, that ~~[[can]]~~ is able to differentiate into myocardial cells by ~~a culture under a condition inducing differentiation into cardiac muscle such as a coculture with cultured~~ myocardial cells.
6. (Currently amended) The isolated monocyte-derived multipotent cell according to claim ~~[[1 or]]~~ 2, that ~~[[can]]~~ is able to differentiate into nerve by ~~a culture under a condition inducing differentiation into nerve, such as a coculture with cultured~~ nerve.
7. (Currently amended) The isolated monocyte-derived multipotent cell according to claim ~~[[1 or]]~~ 2, that ~~[[can]]~~ is able to differentiate into endothelial cells by ~~a culture under a condition inducing differentiation into endothelium, such as a culture under a condition~~ maintaining endothelial cells.

8. (Currently amended) The isolated monocyte-derived multipotent cell according to claim [[1 or]] 2, that [[can]] is able to differentiate into mesodermal cells.
9. (Withdrawn – currently amended) A method for preparing a monocyte-derived multipotent cell according to claim [[1]] 2, comprising culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin, and collecting fibroblast-like cells expressing CD14 and CD34.
10. (Withdrawn) The method for preparing a monocyte-derived multipotent cell according to claim 9, comprising culturing in vitro on fibronectin for 5 to 14 days.
11. (Withdrawn – currently amended) A mesenchymal progenitor, a mesenchymal cell or a mesenchymal tissue induced by culturing the monocyte-derived multipotent cell according to claim [[1 or]] 2, under a condition inducing differentiation into mesenchymal tissues.
12. (Withdrawn) The mesenchymal progenitor, the mesenchymal cell or the mesenchymal tissue according to claim 11, wherein the mesenchymal cells are osteoblasts, skeletal myoblasts, chondrocytes or adipocyte.
13. (Withdrawn – currently amended) A myocardial progenitor, a myocardial cell or a myocardial tissue induced by culturing the monocyte-derived multipotent cell according to claim [[1 or]] 2, under a condition inducing differentiation into cardiac muscle such as a coculture with cultured myocardial cells.
14. (Withdrawn – currently amended) A neural progenitor, a neuron or a nerve tissue induced by culturing the monocyte-derived multipotent cell according to claim [[1 or]] 2, under a condition inducing differentiation into nerve, such as a coculture with cultured neuron.
15. (Withdrawn – currently amended) An endothelial progenitor, an endothelial cell or an endothelial tissue induced by culturing the monocyte-derived multipotent cell according to claim [[1 or]] 2, under a condition inducing differentiation into endothelium, such as a culture under a condition maintaining endothelial cells.

16. (Withdrawn – currently amended) A mesodermal progenitor, a mesodermal cell or a mesodermal tissue induced to differentiate from the monocyte-derived multipotent cell according to claim [[1 or]] 2, under a condition inducing differentiation into mesodermal cell or mesodermal tissue, such as a culture under a condition maintaining mesodermal cells.

17-18. (Cancelled)

19. (Withdrawn – currently amended) A treating method comprising administering the monocyte-derived multipotent cell according to claim [[1 or]] 2 and/or mesodermal progenitors, mesodermal cells and/or mesodermal tissues induced to differentiate from the monocyte-derived multipotent cell.

20. (Withdrawn – currently amended) A treating method comprising administering the monocyte-derived multipotent cell according to claim [[1 or]] 2 and/or neural progenitors, neurons and/or nerve tissues induced to differentiate from the monocyte-derived multipotent cell.

21. (Currently amended) [[A]] The monocyte-derived multipotent cell according to claim [[1]] 2, wherein said monocyte is obtained by culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin, and collecting fibroblast-like cells expressing CD14 and CD34.

22. (Withdrawn) A method for preparing the monocyte-derived multipotent cell according to claim 21, comprising culturing in vitro on fibronectin for 5 to 14 days.